Drugs / Super CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07493044 | Mar 2026 → Apr 2028 expected | hepatocellular carcinoma | Guangzhou FineImmune Biotechnology Co., LTD. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Super CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07493044 ↗ |
| Modality | Cell therapy | “GPC3-Targeted Chimeric Antigen Receptor Autologous T-Cell Injection (Super CAR-T)” NCT07493044 ↗ |
| Target | GPC3 | “GPC3-Targeted Chimeric Antigen Receptor Autologous T-Cell Injection” NCT07493044 ↗ |